Riva Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Riva Therapeutics - overview
Established
2022
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and co-founded by Brion W. Murray (President and CSO), William C. Hahn, Andrew Aguirre, and Francisca Vazque in 2022, Riva Therapeutics operates as a biotechnology company developing transformative medicines for cancer patients. In June 2023, the firm raised approximately USD 3 million in series A funding led by investors Forward Equity Partners and Meritz Securities.
The company specializes in precision oncology and leverages deep knowledge of genomic dependencies to create a new generation of small molecule therapeutics that selectively target essential tumor cell processes beyond DNA damage repair. Riva’s precision lethal therapies aim to provide profound clinical activity, be well-tolerated, and substantially improve patient lives. The company plans to utilize the June 2023 funding to develop anti-cancer drugs.
Current Investors
Novo Holdings, Meritz Securities, Forward Equity Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.rivatherapeutics.com/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.